Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
GORD: pain, PPIs, and preciseness1922
Viral hepatitis: time for action636
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy604
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply504
Lucky: Learning to Live Again441
EASL Congress 2024430
Treatment withdrawal in Crohn's disease: slowly becoming clearer421
Trends in alcohol-specific deaths in the UK and industry responses358
Research in Brief302
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design293
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma287
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled282
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship262
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11256
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30255
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension242
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium237
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus222
Thanks to our peer reviewers and contributors220
Appendicectomy: a disease-modifying treatment for ulcerative colitis?215
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial214
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial207
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response191
Developing policy for steatotic liver disease: an even better buy?185
Correction to Lancet Gastroenterol Hepatol 2026; 11: 314–22177
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement170
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial162
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t161
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study159
ACG 2024144
Long-term VEDOKIDS results: implications for practice and research143
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47141
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply139
Management of portal vein thrombosis in cirrhosis137
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere131
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?129
Water and sanitation for all129
Idiopathic gastroparesis consensus misses the patient's voice128
Research in Brief127
Uptick of food allergies in recent years—real or epiphenomenon?124
Has the time come for a systematic top-down approach in Crohn's disease?123
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply122
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis121
The potential of ctDNA in locoregional therapies for colorectal cancer118
Local and systemic therapy in liver cancer: the quest for synergy118
All roads lead to the gut–brain microbiome network116
Bringing organ preservation closer for selected patients with rectal cancer115
Rare cause of dysphagia in a young woman108
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada100
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study97
Resmetirom for NASH: balancing promise and prudence97
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review97
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial96
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p95
Sex and gender in inflammatory bowel disease outcomes and research93
Availability of point-of-care HBV tests in resource-limited settings93
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial92
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study90
Lifting the minority tax in gastroenterology and hepatology89
Management of malignant bowel obstruction – Authors' reply84
The Year My Life Went Down the Toilet84
A women-focused matrix mentorship programme in gastroenterology83
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B83
Practicalities accessing precision medicine in biliary tract cancer81
Research in Brief79
Another arrow in the NASH quiver?79
18th Congress of the European Crohn's and Colitis Organisation78
An unusual complication after a variceal glue injection77
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions76
Britta Siegmund: answering the big questions in IBD74
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED74
Managing inflammatory bowel disease: what to do when the best is unaffordable?73
Robotic versus laparoscopic surgery for middle and low rectal cancer73
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial73
0.75609707832336